Two randomized migraine studies of galcanezumab

Effects on patient functioning and disability

Janet H. Ford, David W. Ayer, Qi Zhang, Jeffrey N. Carter, Elizabeth Leroux, Vladimir Skljarevski, Sheena K. Aurora, Antje Tockhorn-Heidenreich, Richard B. Lipton

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To evaluate changes from baseline in patient-reported outcomes for measures of functioning and disability among patients with migraine treated with galcanezumab or placebo. METHODS: Patients with episodic migraine (4-14 monthly migraine headache days) were treated with either galcanezumab (Evaluation of LY2951742 in the Prevention of Episodic Migraine [EVOLVE]-1: 120 mg n = 210, 240 mg n = 208; EVOLVE-2: 120 mg n = 226, 240 mg n = 220) or placebo (EVOLVE-1 n = 425; EVOLVE-2 n = 450) during 6 months of treatment. Migraine-Specific Quality of Life Questionnaire v2.1 (MSQv2.1) measured the effect of migraine on patient functioning (physical and emotional) in 3 domains, and the Migraine Disability Assessment (MIDAS) quantified headache-related disability associated with missed or reduced productivity at work or home and social events. Both were collected at baseline and during the treatment period (MSQv2.1 = monthly; MIDAS = months 3 and 6 only). RESULTS: Differences in MSQv2.1 total score least squares (LS) mean change from baseline (month 4-6) for galcanezumab (120 and 240 mg, respectively) were superior to placebo (EVOLVE-1 = 7.3 and 6.7 [both p < 0.001]; EVOLVE-2 = 8.5 and 7.3 [both p < 0.001]). Differences were similar for all domain scores (p < 0.001 for both galcanezumab doses compared with placebo), were observed as early as month 1, and were sustained for 6 months for most domains. Differences of MIDAS LS mean change from baseline (month 6) for galcanezumab (120 and 240 mg, respectively) compared with placebo were: EVOLVE-1 = -6.3 (p < 0.001) and -5.2 (p = 0.002); EVOLVE-2 = -9.2 and -8.2 (both p < 0.001). CONCLUSIONS: Patients with episodic migraine treated with galcanezumab reported significant and clinically meaningful improvements in daily functioning and decreased disability compared with patients who received placebo. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with migraine, galcanezumab (120 mg or 240 mg) given once monthly improved functioning and reduced disability.

Original languageEnglish (US)
Pages (from-to)e508-e517
JournalNeurology
Volume93
Issue number5
DOIs
StatePublished - Jul 30 2019

Fingerprint

Migraine Disorders
Placebos
Quality of Life
Least-Squares Analysis
Headache

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Two randomized migraine studies of galcanezumab : Effects on patient functioning and disability. / Ford, Janet H.; Ayer, David W.; Zhang, Qi; Carter, Jeffrey N.; Leroux, Elizabeth; Skljarevski, Vladimir; Aurora, Sheena K.; Tockhorn-Heidenreich, Antje; Lipton, Richard B.

In: Neurology, Vol. 93, No. 5, 30.07.2019, p. e508-e517.

Research output: Contribution to journalArticle

Ford, JH, Ayer, DW, Zhang, Q, Carter, JN, Leroux, E, Skljarevski, V, Aurora, SK, Tockhorn-Heidenreich, A & Lipton, RB 2019, 'Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability', Neurology, vol. 93, no. 5, pp. e508-e517. https://doi.org/10.1212/WNL.0000000000007856
Ford JH, Ayer DW, Zhang Q, Carter JN, Leroux E, Skljarevski V et al. Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability. Neurology. 2019 Jul 30;93(5):e508-e517. https://doi.org/10.1212/WNL.0000000000007856
Ford, Janet H. ; Ayer, David W. ; Zhang, Qi ; Carter, Jeffrey N. ; Leroux, Elizabeth ; Skljarevski, Vladimir ; Aurora, Sheena K. ; Tockhorn-Heidenreich, Antje ; Lipton, Richard B. / Two randomized migraine studies of galcanezumab : Effects on patient functioning and disability. In: Neurology. 2019 ; Vol. 93, No. 5. pp. e508-e517.
@article{e9ea3b7b2ab54e8abd9bb910587ed4c8,
title = "Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability",
abstract = "OBJECTIVE: To evaluate changes from baseline in patient-reported outcomes for measures of functioning and disability among patients with migraine treated with galcanezumab or placebo. METHODS: Patients with episodic migraine (4-14 monthly migraine headache days) were treated with either galcanezumab (Evaluation of LY2951742 in the Prevention of Episodic Migraine [EVOLVE]-1: 120 mg n = 210, 240 mg n = 208; EVOLVE-2: 120 mg n = 226, 240 mg n = 220) or placebo (EVOLVE-1 n = 425; EVOLVE-2 n = 450) during 6 months of treatment. Migraine-Specific Quality of Life Questionnaire v2.1 (MSQv2.1) measured the effect of migraine on patient functioning (physical and emotional) in 3 domains, and the Migraine Disability Assessment (MIDAS) quantified headache-related disability associated with missed or reduced productivity at work or home and social events. Both were collected at baseline and during the treatment period (MSQv2.1 = monthly; MIDAS = months 3 and 6 only). RESULTS: Differences in MSQv2.1 total score least squares (LS) mean change from baseline (month 4-6) for galcanezumab (120 and 240 mg, respectively) were superior to placebo (EVOLVE-1 = 7.3 and 6.7 [both p < 0.001]; EVOLVE-2 = 8.5 and 7.3 [both p < 0.001]). Differences were similar for all domain scores (p < 0.001 for both galcanezumab doses compared with placebo), were observed as early as month 1, and were sustained for 6 months for most domains. Differences of MIDAS LS mean change from baseline (month 6) for galcanezumab (120 and 240 mg, respectively) compared with placebo were: EVOLVE-1 = -6.3 (p < 0.001) and -5.2 (p = 0.002); EVOLVE-2 = -9.2 and -8.2 (both p < 0.001). CONCLUSIONS: Patients with episodic migraine treated with galcanezumab reported significant and clinically meaningful improvements in daily functioning and decreased disability compared with patients who received placebo. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with migraine, galcanezumab (120 mg or 240 mg) given once monthly improved functioning and reduced disability.",
author = "Ford, {Janet H.} and Ayer, {David W.} and Qi Zhang and Carter, {Jeffrey N.} and Elizabeth Leroux and Vladimir Skljarevski and Aurora, {Sheena K.} and Antje Tockhorn-Heidenreich and Lipton, {Richard B.}",
year = "2019",
month = "7",
day = "30",
doi = "10.1212/WNL.0000000000007856",
language = "English (US)",
volume = "93",
pages = "e508--e517",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Two randomized migraine studies of galcanezumab

T2 - Effects on patient functioning and disability

AU - Ford, Janet H.

AU - Ayer, David W.

AU - Zhang, Qi

AU - Carter, Jeffrey N.

AU - Leroux, Elizabeth

AU - Skljarevski, Vladimir

AU - Aurora, Sheena K.

AU - Tockhorn-Heidenreich, Antje

AU - Lipton, Richard B.

PY - 2019/7/30

Y1 - 2019/7/30

N2 - OBJECTIVE: To evaluate changes from baseline in patient-reported outcomes for measures of functioning and disability among patients with migraine treated with galcanezumab or placebo. METHODS: Patients with episodic migraine (4-14 monthly migraine headache days) were treated with either galcanezumab (Evaluation of LY2951742 in the Prevention of Episodic Migraine [EVOLVE]-1: 120 mg n = 210, 240 mg n = 208; EVOLVE-2: 120 mg n = 226, 240 mg n = 220) or placebo (EVOLVE-1 n = 425; EVOLVE-2 n = 450) during 6 months of treatment. Migraine-Specific Quality of Life Questionnaire v2.1 (MSQv2.1) measured the effect of migraine on patient functioning (physical and emotional) in 3 domains, and the Migraine Disability Assessment (MIDAS) quantified headache-related disability associated with missed or reduced productivity at work or home and social events. Both were collected at baseline and during the treatment period (MSQv2.1 = monthly; MIDAS = months 3 and 6 only). RESULTS: Differences in MSQv2.1 total score least squares (LS) mean change from baseline (month 4-6) for galcanezumab (120 and 240 mg, respectively) were superior to placebo (EVOLVE-1 = 7.3 and 6.7 [both p < 0.001]; EVOLVE-2 = 8.5 and 7.3 [both p < 0.001]). Differences were similar for all domain scores (p < 0.001 for both galcanezumab doses compared with placebo), were observed as early as month 1, and were sustained for 6 months for most domains. Differences of MIDAS LS mean change from baseline (month 6) for galcanezumab (120 and 240 mg, respectively) compared with placebo were: EVOLVE-1 = -6.3 (p < 0.001) and -5.2 (p = 0.002); EVOLVE-2 = -9.2 and -8.2 (both p < 0.001). CONCLUSIONS: Patients with episodic migraine treated with galcanezumab reported significant and clinically meaningful improvements in daily functioning and decreased disability compared with patients who received placebo. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with migraine, galcanezumab (120 mg or 240 mg) given once monthly improved functioning and reduced disability.

AB - OBJECTIVE: To evaluate changes from baseline in patient-reported outcomes for measures of functioning and disability among patients with migraine treated with galcanezumab or placebo. METHODS: Patients with episodic migraine (4-14 monthly migraine headache days) were treated with either galcanezumab (Evaluation of LY2951742 in the Prevention of Episodic Migraine [EVOLVE]-1: 120 mg n = 210, 240 mg n = 208; EVOLVE-2: 120 mg n = 226, 240 mg n = 220) or placebo (EVOLVE-1 n = 425; EVOLVE-2 n = 450) during 6 months of treatment. Migraine-Specific Quality of Life Questionnaire v2.1 (MSQv2.1) measured the effect of migraine on patient functioning (physical and emotional) in 3 domains, and the Migraine Disability Assessment (MIDAS) quantified headache-related disability associated with missed or reduced productivity at work or home and social events. Both were collected at baseline and during the treatment period (MSQv2.1 = monthly; MIDAS = months 3 and 6 only). RESULTS: Differences in MSQv2.1 total score least squares (LS) mean change from baseline (month 4-6) for galcanezumab (120 and 240 mg, respectively) were superior to placebo (EVOLVE-1 = 7.3 and 6.7 [both p < 0.001]; EVOLVE-2 = 8.5 and 7.3 [both p < 0.001]). Differences were similar for all domain scores (p < 0.001 for both galcanezumab doses compared with placebo), were observed as early as month 1, and were sustained for 6 months for most domains. Differences of MIDAS LS mean change from baseline (month 6) for galcanezumab (120 and 240 mg, respectively) compared with placebo were: EVOLVE-1 = -6.3 (p < 0.001) and -5.2 (p = 0.002); EVOLVE-2 = -9.2 and -8.2 (both p < 0.001). CONCLUSIONS: Patients with episodic migraine treated with galcanezumab reported significant and clinically meaningful improvements in daily functioning and decreased disability compared with patients who received placebo. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with migraine, galcanezumab (120 mg or 240 mg) given once monthly improved functioning and reduced disability.

UR - http://www.scopus.com/inward/record.url?scp=85070789663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070789663&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000007856

DO - 10.1212/WNL.0000000000007856

M3 - Article

VL - 93

SP - e508-e517

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 5

ER -